A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for... | NCT02225912 | Trialant
CompletedInterventionalPhase 4Updated Jan 16, 2019
A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers
ClinicalTrials.gov ID
NCT02225912
Lead Sponsor
BioHealth Technologies Inc.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Last Update Posted
Jan 16, 2019Actual
Start Date
Feb 2005
Primary Completion Date
May 2005Actual
Completion Date
May 2005Actual
Brief Summary
The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in child day care centers.
Upper Respiratory Infections
PrevinC
placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Subject must provide written informed consent prior to the conduct of any study
Male or female
18-65 years of age
Inclusive
Employed by one of seven selected Day Care Centers
Exclusion Criteria:
Recent symptoms of upper respiratory infection, respiratory disease
Received medication for colds or allergies within 3 weeks of enrolling